Literature DB >> 27232638

Aldosterone-producing Adenoma in Primary Aldosteronism: CT-guided Radiofrequency Ablation-Long-term Results and Recurrence Rate.

Shirley Yuk Wah Liu1, Charmant Cheuk Man Chu1, Teresa Kam Chi Tsui1, Simon Kin Hung Wong1, Alice Pik Shan Kong1, Philip Wai Yan Chiu1, Francis Chun Chung Chow1, Enders Kwok Wai Ng1.   

Abstract

Purpose To evaluate the long-term biochemical, clinical, and recurrence outcomes of radiofrequency (RF) ablation in treating primary aldosteronism due to aldosterone-producing adenoma (APA). Materials and Methods Institutional review board approval and written informed consent were obtained. The use of computed tomographically (CT) guided percutaneous RF ablation was evaluated in 36 patients (19 men; mean age ± standard deviation, 52.1 years ± 10.4) with APA (17 right and 19 left side; mean size, 15.5 mm ± 5.0). Primary aldosteronism was confirmed by using the oral sodium-loading test. After RF ablation, CT images, aldosterone-to-renin ratio (ARR), serum potassium level, and blood pressure control were assessed at 3 months and at the latest follow-up examination. Long-term treatment success was defined as normalization of ARR at the latest assessment. Comparison of ARR, potassium, and blood pressure levels before and after RF ablation was performed by using the Wilcoxon signed-rank test. Results Primary technical success was achieved in 33 (92%) patients who underwent a single RF ablation session. Secondary technical success was achieved in three (8%) patients who required a second RF ablation. At 3-month follow-up, primary aldosteronism was resolved in 33 (92%) patients, with a starting median ARR of 8583 pmol/L per µg/(L · h) that normalized to 97 pmol/L per µg/(L · h) (P < .01). Mean serum potassium levels increased from 2.6 mmol/L ± 0.4 to 4.0 mmol/L ± 0.3 (P = .01). At long-term follow-up (mean, 6.2 years ± 2.5), treatment success was maintained in 33 patients (92%), all of whom had ARRs in the normal range (P < .01). The long-term recurrence rate was 0%. Hypokalemia was resolved in all patients (2.6 mmol/L ± 0.4 to 4.1 mmol/L ± 0.3, P = .01). Hypertension was resolved in 13 (36%) patients, and its control was improved in seven (19%) patients. One (3%) patient had major complications and six (17%) had minor complications. Conclusion CT-guided RF ablation is an effective treatment for APA, with high sustainable long-term treatment success. It may serve as a justifiable treatment alternative to surgery and medical therapy for APA. © RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27232638     DOI: 10.1148/radiol.2016152277

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  10 in total

Review 1.  Primary aldosteronism.

Authors:  Sean M Wrenn; Anand Vaidya; Carrie C Lubitz
Journal:  Gland Surg       Date:  2020-02

2.  Splenic findings in patients with acute babesiosis.

Authors:  A Mojtahed; D D B Bates; P F Hahn
Journal:  Abdom Radiol (NY)       Date:  2020-03

Review 3.  Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.

Authors:  Heather Wachtel; Douglas L Fraker
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 3.955

Review 4.  Progress in the Management of Primary Aldosteronism.

Authors:  Ryo Morimoto; Kei Omata; Sadayoshi Ito; Fumitoshi Satoh
Journal:  Am J Hypertens       Date:  2018-04-13       Impact factor: 2.689

5.  Diagnostic value of adrenal iodine-131 6-beta-iodomethyl-19-norcholesterol scintigraphy for primary aldosteronism: a retrospective study at a medical center in North Taiwan.

Authors:  Ming-Hsien Wu; Feng-Hsuan Liu; Kun-Ju Lin; Jui-Hung Sun; Szu-Tah Chen
Journal:  Nucl Med Commun       Date:  2019-06       Impact factor: 1.690

6.  Safety and feasibility of radiofrequency ablation using bipolar electrodes for aldosterone-producing adenoma: a multicentric prospective clinical study.

Authors:  Sota Oguro; Ryo Morimoto; Kazumasa Seiji; Hideki Ota; Tomo Kinoshita; Masahiro Kawabata; Yoshikiyo Ono; Kei Omata; Yuta Tezuka; Fumitoshi Satoh; Sadayoshi Ito; Nobukazu Moriya; Seishi Matsui; Tetsuo Nishikawa; Masao Omura; Kazuki Nakai; Seishi Nakatsuka; Isao Kurihara; Kazutoshi Miyashita; Wataru Koda; Tetsuya Minami; Yoshiyu Takeda; Mitsuhiro Kometani; Yutaka Oki; Toshihiro Oishi; Takasuke Ushio; Satoshi Goshima; Kei Takase
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

7.  Immediate Results and Long-Term Outcomes Following Percutaneous Radiofrequency Ablation of Unilateral Aldosterone-Producing Adenoma.

Authors:  Chien-Hsien Lo; Yeu-Sheng Tyan; Kwo-Chang Ueng
Journal:  Acta Cardiol Sin       Date:  2020-03       Impact factor: 2.672

8.  Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial.

Authors:  Hexuan Zhang; Qiang Li; Xiaoli Liu; Zhigang Zhao; Hongbo He; Fang Sun; Yangning Hong; Xunmei Zhou; Yingsha Li; Rufei Shen; Xiaona Bu; Zhencheng Yan; Hongting Zheng; Gangyi Yang; Zhiming Zhu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-27       Impact factor: 3.738

Review 9.  Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation.

Authors:  Byung Kwan Park; Masashi Fujimori; Shu-Huei Shen; Uei Pua
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-01

10.  Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.

Authors:  Béatrice Bouhanick; Marie C Delchier; Séverine Lagarde; Romain Boulestreau; Claude Conil; Philippe Gosse; Hervé Rousseau; Benoit Lepage; Pascale Olivier; Panteleimon Papadopoulos; Hervé Trillaud; Antoine Cremer
Journal:  J Hypertens       Date:  2021-04-01       Impact factor: 4.776

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.